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Background: Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of the metabolic
pathway of 5-fluorouracil (5-FU) and other fluoropyrimidines to inactive compounds. For this reason, severe,
life-threatening toxicities may occur in patients with deficient DPD activity when administered standard doses
of 5-FU and its prodrugs.
Materials and methods: We selected three patients with colorectal adenocarcinoma who displayed unexpected
severe adverse reactions after treatment with 5-FU and capecitabine. To investigate the possible involvement of
deficient variants of the DPD gene (DPYD), a denaturing HPLC (dHPLC) approach followed by target exon
sequencing of DPYD was performed on DNA extracted from peripheral blood.
Results: Three novel non-synonymous mutations of DPYD, c.2509-2510insC, c.1801G>C, and c.680G>A, were
detected in these subjects. Due to the absence of other deficient variants of DPYD and the compatibility of
adverse reactions with fluoropyrimidine treatment, the novel variants were associated with a poor-metabolizer
phenotype.
Conclusions: Stratification of patients on the basis of their genotype may help prevent toxicity, and the large
body of evidence about the pathogenesis of fluoropyrimidine-induced adverse reactions strongly encourages the
adoption of best practice recommendations to appropriately address this important clinical issue. This approach
is of utmost importance within a preventive, prognostic, and personalized approach to patient care in the
oncology setting.
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Fluoropyrimidines, including 5-fluorouracil (5-FU) and its
prodrugs capecitabine and ftorafur/uracil (UFT), are used
for the treatment of solid tumors including colorectal,
breast, pancreatic, and head and neck cancers [1]. Capecit-
abine (N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine) is
an orally administered fluoropyrimidine, which undergoes
extensive metabolism to 5-FU via a three-step enzymatic
process. Capecitabine is first hydrolyzed by carboxylester-
ase in the liver to 5′-deoxy-5-fluorocytidine (5′-DFCR)
and then metabolized to 5′-deoxy-5-fluorouridine (5′-
DFUR) by cytidine deaminase. 5′-DFUR is finally con-
verted to 5-FU by thymidine phosphorylase [2]. The initial
rate-limiting step of the inactivation of 5-FU to dihydro-
fluorouracil occurs via dihydropyrimidine dehydrogenase
(DPD), a ubiquitous enzyme mostly represented in the
liver. Mutations in the DPD gene (DPYD) may comprom-
ise its activity and cause severe toxicity in patients given
standard doses of fluoropyrimidines [3]. A number of gen-
etic variants of DPYD associated with the deficient pheno-
type have been described [4], although the full spectrum
of mutations is unknown thus far. The knowledge of the
poor-metabolizer status in the individual patient is
mandatory to allow safe administration of chemothera-
peutic drugs to meet the general principle of preventive,
prognostic, and personalized medicine for optimal oncol-
ogy care. This article reports on three novel mutations of
DPYD in patients treated with 5-FU or capecitabine and
experiencing unexpected life-threatening toxicities and
discusses the importance of developing best clinical la-
boratory practice recommendations for the use of pre-
emptive genetic screening of DPYD.
Methods
Blood samples were obtained from a peripheral vein of
three patients with severe toxicities, as described below,
and DNA extraction was performed using Qiagen Bioro-
bot® (Qiagen, CA, USA). The full coding region of DPYD
was amplified by PCR, and the presence of sequence
variants was screened by denaturing high-performance li-
quid chromatography (dHPLC; Transgenomic, CT, USA).
dHPLC uses heteroduplex formation between wild-type
and mutated DNA strands to identify mutations. Hetero-
duplex molecules are then separated from homoduplex
molecules by ion-pair, reverse-phase liquid chromatog-
raphy on a column matrix with partial heat denaturation
of the DNA strands. The temperature for optimal reso-
lution of heteroduplex and homoduplex DNA was deter-
mined by analyzing the melting behavior of a PCR
fragment of each exon while the temperature was in-
creased by 1 °C steps from 50 to 55 °C until the fragment
was completely melted. The temperature chosen for ana-
lysis of each fragment was the point at which 75 % of the
DNA was present as an alpha helix or 1 to 2 °C higher [5].When an aberrant dHPLC pattern was detected, then
exon analysis was performed by automatic sequencing on
an ABI PRISM 3700 DNA Analyzer using the 3100 Big-
Dye® Terminator v3.1 Cycle Sequencing Kit (Life Tech-
nologies, CA, USA).
A 68-year-old woman was diagnosed with metastatic
colon carcinoma and treated with irinotecan 180 mg/m2,
leucovorin 400 mg/m2, and 5-FU 400 mg/m2 i.v. bolus
followed by 2800 mg/m2 continuous infusion over 46 h
and bevacizumab 5 mg/kg. Toxicity occurred after the
first cycle and is described in Table 1. The patient recov-
ered after 23 days, and a second cycle of treatment was
started with an empirical dose reduction of both irinote-
can (30 %) and 5-FU (75 %). The patient suffered again
from toxicity that appeared 7 days from the administra-
tion of chemotherapy and recovered after 2 weeks.
Treatment was started again with a further dose reduc-
tion of 5-FU (85 %), but owing to the poor tolerability, it
was eventually discontinued. A second patient was a 57-
year-old woman previously diagnosed with a sigmoid
carcinoma and given oxaliplatin 85 mg/m2, folinic acid
200 mg/m2, and 5-FU i.v. bolus 400 mg/m2 followed by
a 44-h continuous infusion of 400 mg/m2 i.v. Toxicity
occurred after the second cycle and is described in
Table 1. Recovery from toxicity was slow and occurred
at day 23. The last case was a 59-year-old woman given
adjuvant treatment with capecitabine 1000 mg/m2 twice
daily for 14 days plus oxaliplatin 130 mg/m2 every
3 weeks for a surgically resected B2 colon carcinoma.
On day 14 of the first cycle, the patient developed severe
gastrointestinal and hematological toxicities (Table 1).
Treatment was discontinued and the patient was hospi-
talized; her toxicity recovered at day 27.
The procedures described in the present report have been
approved by the local ethics committee of University
Hospital, Pisa, Italy (protocol n. 3268/2011). All patients were
provided with a written detailed description of the experimen-
tal procedures of this study and gave their informed consent.
Results
Several polymorphic variants of DPYD have been reported
(Table 2). The IVS14+1G>A and c.2846A>T are the most
common variants associated with profound DPD defi-
ciency and severe toxicities [6, 7]. However, these muta-
tions were not detected in the present patients. The first
subject was heterozygous for the novel c.2509-2510insC
and was also carrier of the previously described c.85TC se-
quence variant. The c.2509-2510insC leads to a leucine-
proline substitution in the exon 20 and causes misreading
of the coding sequence, altering DPYD transcription and
enzyme activity. The second patient presented the novel
c.1801GC variant, which causes a missense mutation
changing a glycine into a serine, as well as the previously
described c.85TC, c.1801GC, and cc.2194AA variants.
Table 1 Type of treatment, genotype, and toxicities graded according to NCI-CTCAE v.4.03 criteria, where 0 is absence of the specific
adverse reaction and 4 is the worst grade, in the patients of the present study
Patient 1 2 3
Treatment Irinotecan 180 mg/m2, leucovorin
400 mg/m2, and 5-FU 400 mg/m2
i.v. bolus followed by 2800 mg/m2
continuous infusion over 46 h and
bevacizumab 5 mg/kg
Oxaliplatin 85 mg/m2, folinic acid
200 mg/m2, and 5-FU i.v. bolus
400 mg/m2 followed by a 44-h
continuous infusion of 400 mg/m2 i.v.
Capecitabine 1000 mg/m2
twice daily for 14 days plus
oxaliplatin 130 mg/m2 every
3 weeks
Genotype c.2509-2510insC c.85TC c.680GA
c.85TC c.1801GC c.2194GA
cc.2194AA
Toxicity Grade of severity
Nausea/vomiting 0 2 4
Diarrhea 4 3 0
Stomatitis 3 4 3
Leukopenia 2 0 4
Neutropenia 2 0 4
Hand-foot syndrome 0 3 1
Anemia 0 0 2
Fever 0 0 4
Table 2 DPYD variants detected in patients with adverse
reactions to fluoropyrimidines
Exon/intron Variant Reference
2 c.61C>T, c.62G>A, c.74A>G, c.85T>C [11, 18, 19]
3 c.187A>G [8]
4 c.257C>T [19]
5 c.464T>A [20]
6 c.496A>G, c.601A>C [19, 21]
7 c.703C>T [22]
8 c.775A>G, c.812delT [23, 24]
10 c.1003G>T, c.1039delTG, c.1050G>A,
c.1109delTA, c.1108A>G
[8, 11, 19, 21]
11 c.1156G>T [11]
12 c.1358C>T [25]
13 c.1590T>C, c.1601G>A, c.1627A>G,
c.1679T>G, c.1714C>G
[11, 18, 19, 24, 26]
14 c.1896T>C, c.1897delC [11, 27]
18 c.2194G>A [19]
22 c.2846A>T [13, 18, 21]
23 c.2933A>G [19]
Intron 6 IVS6-29G>T [28]
Intron 10 IVS10-15T>C [21]
Intron 14 IVS14+1G>A [13, 27]
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tion c.680GA, which causes a serine-glycine change,
combined with the previously described c.2194GA geno-
type. Therefore, the insertion c.2509-2510insC as well as
the c.1801G>C and c.680G>A are novel mutations not pre-
viously reported and are associated with fluoropyrimidine-
induced toxicity.
Conclusions
The role of DPYD deficient variants as a cause of
fluoropyrimidine-induced toxicity is still a debated issue
[7]. In the present study, we identified three novel muta-
tions within DPYD, together with other known sequence
variants. The role of c.85T>C is uncertain; in previous
studies, c.85T>C has not been correlated with gastro-
intestinal toxicity [8] and has apparently no functional
significance on DPD activity [9]. It is likely that c.85T>C
does not cause DPD deficiency by itself [10] but may po-
tentiate the detrimental effect of the genetic variants
with which it is combined. The novel c.1801G>C muta-
tion was found in combination with the homozygous
c.2194AA; even if the latter is associated with modest 5-
FU toxicity [11], the novel mutation could represent a
detrimental variant and increase the effect of other
single nucleotide polymorphisms. The novel c.680GA
was present in the third patient in association with
c.2194GA; since c.2194GA has not been implicated in
severe toxicities in patients treated with fluoropyrimidines,
the new mutation c.680GA could play a critical role in this
setting. In each case, a different amino acid is incorpo-
rated into the mutated protein as a consequence of the
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have functional consequences. In the first case, bearing
the c.2509-2510insC, leucine and proline share some simi-
larities, being both hydrophobic, but the distinctive cyclic
structure of proline’s side chain gives this amino acid an
exceptional conformational rigidity compared to other
amino acids while leucine possesses an aliphatic side chain
that is non-linear and prefers to be buried in protein
hydrophobic cores. Indeed, their substitution in enzymes
can cause profound destabilization [12]. In the second and
third cases, the differences in amino acid properties are
even more pronounced since serine is a polar amino acid
and may participate in hydrogen bonds, while glycine is
hydrophobic and is normally buried inside the protein
core. The outlined characteristics of the amino acids being
substituted in the DPD enzyme provide a justification of
the change in DPD activity although a functional enzym-
atic assay was not performed in these patients because
they were lost to follow-up before the enzyme assay was
available in our laboratory.
Being the number of deficient variants of DPD quite
large, the crucial issue is if it is necessary to investigate
all of them [13].
This uncertainty has made a trial-and-error attitude
very common in the oncology community, which has
followed an empiric approach thus far with respect to
prediction and prevention of fluoropyrimidine-induced
toxicity in cancer patients. Unfortunately, this approach
exposes a significant proportion of patients to the risk of
severe and life-threatening toxicities, even though meta-
analyses demonstrated the strong association between
deficient variants and development of adverse events
[14]. Nevertheless the scientific evidence about the use-
fulness of a targeted pharmacogenetic approach has
been clearly recognized [15]. However, the main reason
for the limited diffusion of preemptive DPD testing are
the costs associated with the analysis [16], owing to the
quite large number of deficient DPYD variants associ-
ated with impaired DPD activity and risk of toxicity.
The issue of application of an optimal preventive,
prognostic, and personalized medicine approach to pa-
tient care is the object of active discussion and has been
addressed by the EPMA in the white paper where a
number of recommendations have been made [17].
Therefore, to help implement DPYD genotyping in clin-
ical practice, a working group of the Italian Association
of Medical Oncology and the Italian Society of Pharma col-
ogy (http://www.sifweb.org/docs/sif_aiom_position_paper_
raccomand_farmacogen_gen15.pdf, last accessed 22 July
2015) released a statement concerning the screening of
major DPYD deficient variants, including IVS14
+1G>A, c.1679T>G, and c.2846A>T, and recom-
mended it to be performed before treatment with fluoro-
pyrimidines, whenever the proposed treatment is plannedin one or more of these conditions: (a) patient at risk (i.e.,
comorbidity, performance status, disease stage), (b) limited
therapeutic advantage in terms of survival and/or response,
(c) high ratio of risk/benefits or (d) in case of G ≥ 3 gastro-
intestinal or G = 4 hematological toxicities (NCI-CTCAE
v4.0) during fluoropyrimidine treatment, and (e) in every
case of unexpected adverse reaction.
In conclusion, the novel polymorphisms detected in
these subjects increase our knowledge about the causes
of unexpected life-threatening toxicities in patients
treated with fluoropyrimidines. The effort of future stud-
ies will be the appropriate identification of at risk muta-
tions in order to avoid inappropriate drug dosing in
poor-metabolizer patients candidate to adjuvant fluoro-
pyrimidine treatment and implement their preemptive
screening in current clinical practice.
Expert recommendations
The present manuscript describes three novel variants of
DPYD associated with unexpected severe toxicities in pa-
tients treated with fluoropyrimidines. It is suggested that,
as a strategic component of the preventive, prognostic,
and personalized approach to improve the efficacy vs. tox-
icity ratio, a preemptive screening of deficient DPD vari-
ants should be performed in patients as a part of standard
healthcare. However, due to the considerable number of
DPYD mutations and to balance the costs vs. benefits, the
analysis of the most frequent variants associated with
DPD deficiency, i.e., IVS14+1G>A, c.1679T>G, and
c.2846A>T, should be performed before treatment, while
the detection of additional rare mutations is recom-
mended in patients suffering from unexpected severe tox-
icities early after the beginning of treatment, until more
affordable technological platforms will allow a cost-
effective analysis of all deficient variants associated with
the poor-metabolizer status.
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